Tamtam Try Tamtam free
Legend Biotech logo

Legend Biotech account plan

Developing novel therapies

At a glance

Legend Biotech develops and makes CAR-T cell therapies, led by CARVYKTI with Janssen; FY2025 revenue $1,028.9 million, about 3,300 employees.

Legend Biotech is a Cayman Islands holding company that discovers, develops, manufactures and commercialises cell therapies for oncology, operating through subsidiaries in the United States, China and Europe, with principal offices in Somerset, New Jersey. Its one approved product, CARVYKTI (cilta-cel), is an autologous BCMA CAR-T for relapsed or refractory multiple myeloma, co-developed and co-commercialised with Janssen (Johnson & Johnson) on a 50/50 cost and profit split worldwide and 70/30 in Greater China. FY2025 total revenue was $1,028.9 million (FY2024: $627.3 million), with an operating loss of $136.5 million and a net loss of $296.8 million. The company had 2,965 employees at December 31, 2025 and now describes a team of approximately 3,300. Genscript owns about 47% of the shares.

Business units

Strategic priorities

Maximise CARVYKTI
CEO Ingrid Zhang's first priority; management keeps a $5 billion-plus peak potential, driven by earlier lines, frontline studies and global expansion. Second- and third-line patients were 50% of U.S. apheresis volume in Q3 2026, up from 29% in Q1 2025.
Next-generation pipeline, led by in vivo CAR-T
LB2501 showed 100% ORR and CR at dose level 2 (8 patients); a U.S. Phase Ia will confirm dose before a Phase Ib across DLBCL, MCL and CLL. LB2505, a BCMA in vivo CAR-T, falls under the Johnson & Johnson agreement.
Sustained profitability
Q2 2026 was the first quarter of company-wide profitability; the goal is full-year 2026 profitability on an adjusted net income basis, with double-digit CARVYKTI growth expected in 2027.
Gross margin expansion
Gross margin reached 58% on manufacturing efficiencies; Q4 2026 is expected in the high 50% range, and the CFO sees "a clear path to 75%" over time.
Frontline readouts
CARTITUDE-5 and CARTITUDE-6 are event-driven; CARTITUDE-5 could read out in 2027 at the soonest, with CARTITUDE-6 later.

Latest results

In Q3 2026 total revenue was $359.5 million (Q3 2025: $272.4 million), of which collaboration revenue $353.2 million. Operating income was $46.8 million against an operating loss of $43.3 million a year earlier, and net income $51.7 million against a $39.6 million loss; adjusted net income was $55.6 million. R&D fell to $95.3 million as major cilta-cel trials finished dosing. Over nine months revenue was $1,052.1 million and net income $30.6 million, against a net loss of $266.0 million. The company gives no formal guidance, but the CFO said Q4 sales consensus sits at the higher end of internal scenarios and expects double-digit CARVYKTI growth in 2027.

Investments and deals

Manufacturing capacity
Capex was $69.3 million in 2025 and is expected to increase, mainly in the United States, the EU and China; under the Raritan Supply Agreement (effective February 2, 2026) Legend supplies cilta-cel to Janssen worldwide excluding Greater China at cost plus a markup.
June 2026 equity offering
7,700,000 ADSs at $29.35 per ADS raised net proceeds of about $211.6 million, described as opportunistic after the in vivo data and giving better business-development optionality.
Settling Janssen funding advances
Janssen is recouping $319.1 million of funding advances and interest from Legend's profit share in 2026; the remaining advance was $44.1 million at September 30, 2026.
Collaboration assets prepayment
Nine-month 2026 investing outflows included a $46.6 million prepayment to Janssen for collaboration assets and $20.6 million of property, plant and equipment.

Challenges and risks

Dependence on one product and one partner
The company depends on CARVYKTI's commercial success and on Janssen to market and sell it.
Competition from bispecifics and other BCMA therapies
Management calls the space increasingly competitive, with strong uptake of bispecifics, including Janssen's own TECVAYLI, in earlier lines; U.S. earlier-line share growth was slower than anticipated.
Manufacturing complexity and suppliers
Risks include manufacturing complexity and capacity, reliance on CMOs and a limited number of suppliers, including for lentiviral vectors.
Ex-U.S. launch timing
The CFO cited ex-U.S. launch delays as one reason Q4 2026 consensus sits at the higher end of scenarios.
China and pricing exposure
PRC legal, regulatory, data and currency risks, an advance pricing agreement still under negotiation with Chinese tax authorities, and U.S. drug pricing policies.

What leadership says

“We remain focused on disciplined execution, expanding access to CARVYKTI worldwide, advancing our innovative pipeline, and delivering sustained profitability.”

Ingrid Zhang, Chief Executive Officer · Q3 2026 earnings release (Form 6-K), November 10, 2026

“number one, maximize CARVYKTI; number two, advance our next-generation pipeline; and number three, strengthen execution on all fronts to deliver sustained profitability.”

Ingrid Zhang, Chief Executive Officer · Q3 2026 earnings call, November 10, 2026, her first as CEO

“it's really not about which product you choose, it's really about the sequence in which you offer them.”

Alan Bash, President, CARVYKTI · Q3 2026 earnings call, November 10, 2026, on competition from bispecifics

“This is a leadership transition, not a strategy transition. Our priorities remain unchanged.”

Alan Bash, then Interim Chief Executive Officer · Q2 2026 earnings call, August 11, 2026

Where a supplier can help

Manufacturing scale-up and efficiency
With capex expected to rise and a gross margin target path towards 75%, suppliers of cell-therapy manufacturing equipment, automation and process consulting can support the Raritan, Ghent and Nanjing sites.
Supply-chain resilience for vectors and materials
The stated reliance on a limited number of suppliers, including for lentiviral vectors, opens room for second-source material and logistics providers.
In vivo CAR-T clinical development
The U.S. Phase Ia and Phase Ib plan for LB2501 points to needs for CRO, clinical-site and trial-data services as the pipeline becomes the second priority.
Commercial reach in earlier lines and new markets
Growth depends on earlier-line uptake in the U.S. and new launches outside it; physician education, market-access and patient-support services fit the priority to maximise CARVYKTI.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Legend Biotech?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Legend Biotech

What does Legend Biotech do?

Legend Biotech discovers, develops, manufactures and commercialises cell therapies. Its approved product, CARVYKTI, is a BCMA CAR-T for relapsed or refractory multiple myeloma sold with Janssen, and its pipeline includes in vivo and allogeneic CAR-Ts.

What was Legend Biotech's revenue?

FY2025 total revenue was $1,028.9 million, up from $627.3 million in FY2024. Revenue for the first nine months of 2026 was $1,052.1 million.

How many employees does Legend Biotech have?

It had 2,965 employees at December 31, 2025 (1,461 United States, 992 Europe, 512 Asia-Pacific) and now describes a team of approximately 3,300.

Who leads Legend Biotech?

Ingrid Zhang became CEO on September 15, 2026, succeeding interim CEO Alan Bash, who returned to President, CARVYKTI. Carlos Santos Garcia is CFO, and Genscript co-founder Fangliang Zhang chairs the board.

Is Legend Biotech profitable?

Q2 2026 was its first quarter of company-wide profitability, and nine-month 2026 net income was $30.6 million against a $266.0 million loss a year earlier. The goal is full-year 2026 profitability on an adjusted net income basis.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)